HRP20171063T1 - Lijek za uklanjanje dušika za uporabu u postupku liječenja poremećaja nakupljanja dušika - Google Patents

Lijek za uklanjanje dušika za uporabu u postupku liječenja poremećaja nakupljanja dušika Download PDF

Info

Publication number
HRP20171063T1
HRP20171063T1 HRP20171063TT HRP20171063T HRP20171063T1 HR P20171063 T1 HRP20171063 T1 HR P20171063T1 HR P20171063T T HRP20171063T T HR P20171063TT HR P20171063 T HRP20171063 T HR P20171063T HR P20171063 T1 HRP20171063 T1 HR P20171063T1
Authority
HR
Croatia
Prior art keywords
hpn
phenylbutyrate
ammonia
glyceryl tri
level
Prior art date
Application number
HRP20171063TT
Other languages
English (en)
Croatian (hr)
Inventor
Bruce Scharschmidt
Masoud MOKHTARANI
Original Assignee
Horizon Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171063(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics, Llc filed Critical Horizon Therapeutics, Llc
Publication of HRP20171063T1 publication Critical patent/HRP20171063T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/175383—Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
HRP20171063TT 2011-09-30 2012-03-09 Lijek za uklanjanje dušika za uporabu u postupku liječenja poremećaja nakupljanja dušika HRP20171063T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US201161564668P 2011-11-29 2011-11-29
EP12835407.3A EP2760479B1 (en) 2011-09-30 2012-03-09 Nitrogen scavenging drug for use in a method of treating a nitrogen retention disorder
PCT/US2012/028620 WO2013048558A2 (en) 2011-09-30 2012-03-09 Methods of therapeutic monitoring of nitrogen scavenging drugs

Publications (1)

Publication Number Publication Date
HRP20171063T1 true HRP20171063T1 (hr) 2017-10-06

Family

ID=47892277

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171063TT HRP20171063T1 (hr) 2011-09-30 2012-03-09 Lijek za uklanjanje dušika za uporabu u postupku liječenja poremećaja nakupljanja dušika

Country Status (25)

Country Link
US (21) US8404215B1 (enExample)
EP (2) EP3263102A1 (enExample)
JP (2) JP6073898B2 (enExample)
KR (2) KR20140094517A (enExample)
CN (2) CN104039358A (enExample)
AU (2) AU2012316750B2 (enExample)
BR (1) BR112014007357B1 (enExample)
CA (1) CA2850391A1 (enExample)
CL (1) CL2014000783A1 (enExample)
CY (1) CY1119028T1 (enExample)
DK (1) DK2760479T3 (enExample)
ES (1) ES2629859T3 (enExample)
HR (1) HRP20171063T1 (enExample)
HU (1) HUE035220T2 (enExample)
IL (2) IL231732A (enExample)
LT (1) LT2760479T (enExample)
MX (2) MX366197B (enExample)
PL (1) PL2760479T3 (enExample)
PT (1) PT2760479T (enExample)
RS (1) RS56196B1 (enExample)
SG (1) SG11201400781TA (enExample)
SI (1) SI2760479T1 (enExample)
SM (1) SMT201700321T1 (enExample)
WO (1) WO2013048558A2 (enExample)
ZA (1) ZA201401851B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012316750B2 (en) 2011-09-30 2017-08-31 Immedica Pharma Ab Methods of therapeutic monitoring of nitrogen scavenging drugs
JP6234436B2 (ja) * 2012-04-20 2017-11-22 ホライゾン セラピューティクス，エルエルシー フェニル酢酸プロドラッグの治療モニタリングの方法
HK1210699A1 (en) * 2012-11-21 2016-05-06 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
US20150094278A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
SI2986325T1 (sl) 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine
EP3782610A1 (en) 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
CA3068041C (en) * 2017-07-03 2024-06-25 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
EP3672620A1 (en) * 2017-08-22 2020-07-01 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CA3184989A1 (en) * 2020-07-07 2022-01-13 Christopher D. Schelling Methods of administering taste masked phenylbutyrate and compositions therefor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
MX2007006171A (es) * 2004-11-26 2007-10-08 Ucl Business Plc Composiciones que comprenden ornitina y acetato.
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
PT3133396T (pt) 2008-08-29 2018-12-07 Immedica Pharma Ab Métodos de tratamento utilizando fármacos eliminadores de amoníaco
CA2735234A1 (en) 2008-08-29 2010-03-04 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs
BR112012001465B1 (pt) 2009-07-24 2021-08-31 Baylor College Of Medicine Uso de um fenilbutirato, sal, éster ou pró-fármaco do mesmo
JP5763638B2 (ja) 2010-07-16 2015-08-12 第一三共株式会社 アルコール類の酸化方法
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
AU2012316750B2 (en) 2011-09-30 2017-08-31 Immedica Pharma Ab Methods of therapeutic monitoring of nitrogen scavenging drugs
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
JP6234436B2 (ja) 2012-04-20 2017-11-22 ホライゾン セラピューティクス，エルエルシー フェニル酢酸プロドラッグの治療モニタリングの方法
HK1210699A1 (en) 2012-11-21 2016-05-06 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
US20150094278A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
SI2986325T1 (sl) 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine
WO2015063659A1 (en) 2013-10-30 2015-05-07 Lupin Limited Process for the preparation of glycerol phenylbutyrate
ES2748294T3 (es) 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Also Published As

Publication number Publication date
US20190125713A1 (en) 2019-05-02
US10045959B1 (en) 2018-08-14
AU2012316750A1 (en) 2014-03-27
CN104039358A (zh) 2014-09-10
US10183006B2 (en) 2019-01-22
EP3263102A1 (en) 2018-01-03
US20180263948A1 (en) 2018-09-20
MX2014003854A (es) 2014-10-17
US20180221325A1 (en) 2018-08-09
BR112014007357B1 (pt) 2022-12-06
KR102019000B1 (ko) 2019-09-05
AU2012316750B2 (en) 2017-08-31
JP2014532179A (ja) 2014-12-04
EP2760479A4 (en) 2015-08-26
JP2017067791A (ja) 2017-04-06
US20180221324A1 (en) 2018-08-09
PL2760479T3 (pl) 2017-09-29
US8404215B1 (en) 2013-03-26
CL2014000783A1 (es) 2015-01-16
SG11201400781TA (en) 2014-04-28
US20160199332A1 (en) 2016-07-14
US20180263949A1 (en) 2018-09-20
LT2760479T (lt) 2017-07-10
US20180055807A1 (en) 2018-03-01
JP6425746B2 (ja) 2018-11-21
US10183005B2 (en) 2019-01-22
KR20180085823A (ko) 2018-07-27
US20180021291A1 (en) 2018-01-25
US9962359B2 (en) 2018-05-08
US9999608B2 (en) 2018-06-19
IL231732A (en) 2017-09-28
US20180021293A1 (en) 2018-01-25
RS56196B1 (sr) 2017-11-30
SMT201700321T1 (it) 2017-09-07
US9254278B2 (en) 2016-02-09
IL254134A0 (en) 2017-10-31
US20130085179A1 (en) 2013-04-04
MX2019006900A (es) 2019-09-04
US20180221326A1 (en) 2018-08-09
MX366197B (es) 2019-06-25
WO2013048558A2 (en) 2013-04-04
DK2760479T3 (en) 2017-07-17
US10183002B2 (en) 2019-01-22
IL231732A0 (en) 2014-05-28
ES2629859T3 (es) 2017-08-16
BR112014007357A2 (pt) 2017-04-04
CN107271696A (zh) 2017-10-20
US20180235920A1 (en) 2018-08-23
AU2017251691A1 (en) 2017-11-09
WO2013048558A3 (en) 2014-04-03
HUE035220T2 (hu) 2018-05-02
US9962358B2 (en) 2018-05-08
US20160199334A1 (en) 2016-07-14
CA2850391A1 (en) 2013-04-04
PT2760479T (pt) 2017-07-21
SI2760479T1 (sl) 2017-07-31
US20130210914A1 (en) 2013-08-15
US9095559B2 (en) 2015-08-04
US20160202240A1 (en) 2016-07-14
EP2760479B1 (en) 2017-05-03
US10183003B2 (en) 2019-01-22
CY1119028T1 (el) 2018-01-10
US10617665B2 (en) 2020-04-14
US10183004B2 (en) 2019-01-22
US20180015064A1 (en) 2018-01-18
US10045958B1 (en) 2018-08-14
KR20140094517A (ko) 2014-07-30
US20150335605A1 (en) 2015-11-26
US20160081969A1 (en) 2016-03-24
JP6073898B2 (ja) 2017-02-01
ZA201401851B (en) 2018-05-30
US20160199333A1 (en) 2016-07-14
US9326966B2 (en) 2016-05-03
US20210000784A1 (en) 2021-01-07
US20180221327A1 (en) 2018-08-09
EP2760479A2 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
HRP20171063T1 (hr) Lijek za uklanjanje dušika za uporabu u postupku liječenja poremećaja nakupljanja dušika
JP2014532179A5 (enExample)
HRP20231478T1 (hr) Csf1r inhibitori za primjenu u liječenju raka
SI2922576T1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
HRP20170651T1 (hr) Hpn-100 za uporabu za liječenje poremećaja retencije dušika
JP2016503398A5 (enExample)
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
ATE486593T1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
HRP20201386T1 (hr) Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat
HRP20230253T1 (hr) Stabilna farmaceutska kompozicija za oralnu administraciju
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
JP2015537000A5 (enExample)
Combrisson et al. Comparative effects of xylazine and propofol on the urethral pressure profile of healthy dogs
HRP20161222T1 (hr) Postupci liječenja koristeći lijekove za izbacivanje amonijaka
ECSP12012360A (es) Preparación recubierta con partículas finas
UA87513C2 (ru) Фармацевтическая композиция, содержащая дроспиренон и этинилэстрадиол
Samnieng Prevalence of dental fear and its relationship with oral health in children
ME02839B (me) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
HRP20170962T1 (hr) Parenteralna farmaceutska formulacija u suspenziji, s produljenim otpuštanjem, u niskom i ultraniskom doziranju, u hormonskoj terapiji klimakteričnog sindroma
Lee et al. Effect of platycodin D on airway MUC5AC mucin production and gene expression induced by growth factor and proinflammatory factor
Lee et al. Oral administration of fermented wild ginseng ameliorates DSS-induced acute colitis by inhibiting NF-kB signaling and protects intestinal epithelial barrier
RU2004134297A (ru) СПОСОБ АВТОМАТИЧЕСКОГО РЕГУЛИРОВАНИЯ ВЕЛИЧИНЫ pH ВОДНЫХ РАСТВОРОВ
HRP20210998T1 (hr) Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met
DAI Anti-lipopolysaccharide effect of ultrafine granular powder of Houttuynia cordata
윤영주 et al. The effect of irradiated allogenic cancellous bone combined with tetracycline on local bone formation in a rat calvarial model